25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Aptevo Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Aptevo Therapeutics Inc together

I guess you are interested in Aptevo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aptevo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aptevo Therapeutics Inc

I send you an email if I find something interesting about Aptevo Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Aptevo Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Aptevo Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.02
When do you have the money?
1 year
How often do you get paid?
7.5%

What is your share worth?

Current worth
$0.42
Expected worth in 1 year
$-28.58
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$-28.98
Return On Investment
-332.0%

For what price can you sell your share?

Current Price per Share
$8.73
Expected price per share
$5.2244 - $13.48
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aptevo Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$8.73
Intrinsic Value Per Share
$265.66 - $331.82
Total Value Per Share
$266.08 - $332.24

2.2. Growth of Aptevo Therapeutics Inc (5 min.)




Is Aptevo Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$4.4m$18m-$11.2m-165.4%

How much money is Aptevo Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$5.9m$6.8m-$12.8m-215.8%
Net Profit Margin-163.6%-243.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Aptevo Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#696 / 945

Most Revenue
#614 / 945

Most Profit
#465 / 945

Most Efficient
#496 / 945
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aptevo Therapeutics Inc?

Welcome investor! Aptevo Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Aptevo Therapeutics Inc.

First you should know what it really means to hold a share of Aptevo Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Aptevo Therapeutics Inc is $8.73. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aptevo Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aptevo Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.42. Based on the TTM, the Book Value Change Per Share is $-7.25 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.52 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aptevo Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.48-5.5%-5.98-68.5%-13.43-153.8%-10.57-121.1%-22.98-263.3%
Usd Book Value Change Per Share-0.85-9.7%-7.25-83.0%-0.52-6.0%-1.95-22.4%0.010.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.9911.3%0.505.7%
Usd Total Gains Per Share-0.85-9.7%-7.25-83.0%-0.52-5.9%-0.96-11.0%0.515.8%
Usd Price Per Share0.18-1.34-1.54-7.86-4.75-
Price to Earnings Ratio-0.09--0.07--0.03--0.12--0.06-
Price-to-Total Gains Ratio-0.21--0.15-0.13-0.05-0.00-
Price to Book Ratio0.43-0.30-0.04-0.59-0.30-
Price-to-Total Gains Ratio-0.21--0.15-0.13-0.05-0.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.73
Number of shares114
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.99
Usd Book Value Change Per Share-7.25-1.95
Usd Total Gains Per Share-7.25-0.96
Gains per Quarter (114 shares)-825.98-109.63
Gains per Year (114 shares)-3,303.93-438.54
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12-3306-3314452-890-449
24-6611-6618903-1780-888
35-9917-99221355-2671-1327
47-13223-132261807-3561-1766
59-16529-165302258-4451-2205
611-19834-198342710-5341-2644
713-23140-231383162-6232-3083
815-26446-264423614-7122-3522
916-29752-297464065-8012-3961
1018-33057-330504517-8902-4400

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%4.036.00.010.0%4.036.00.010.0%
Book Value Change Per Share0.04.00.00.0%4.08.00.033.3%7.013.00.035.0%12.025.03.030.0%12.025.03.030.0%
Dividend per Share1.00.03.025.0%3.00.09.025.0%3.00.017.015.0%3.00.037.07.5%3.00.037.07.5%
Total Gains per Share0.04.00.00.0%5.07.00.041.7%8.012.00.040.0%13.024.03.032.5%13.024.03.032.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aptevo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.849-7.249+754%-0.522-39%-1.952+130%0.010-8204%
Book Value Per Share--0.4198.750-95%36.077-99%18.910-98%77.737-99%
Current Ratio--1.7022.007-15%3.610-53%2.562-34%2.881-41%
Debt To Asset Ratio--0.7080.643+10%0.426+66%0.659+8%0.506+40%
Debt To Equity Ratio--2.4271.923+26%0.757+220%4.949-51%2.800-13%
Dividend Per Share---0.004-100%0.004-100%0.991-100%0.495-100%
Enterprise Value---1076385.094981760.703-210%9532375.818-111%4282280.892-125%8128960.912-113%
Eps---0.484-5.976+1136%-13.427+2677%-10.570+2086%-22.982+4652%
Ev To Ebitda Ratio--0.052-0.034+165%-0.253+581%-0.132+353%-0.104+299%
Ev To Sales Ratio--infnannan%infnan%nannan%nannan%
Free Cash Flow Per Share---0.495-5.607+1033%-6.216+1156%-9.282+1775%-18.156+3567%
Free Cash Flow To Equity Per Share---0.030-3.688+12328%-1.744+5779%-1.121+3678%-0.631+2026%
Gross Profit Margin--1.0001.0000%1.0000%1.009-1%1.024-2%
Intrinsic Value_10Y_max--331.819--------
Intrinsic Value_10Y_min--265.662--------
Intrinsic Value_1Y_max---17.995--------
Intrinsic Value_1Y_min---17.706--------
Intrinsic Value_3Y_max---15.013--------
Intrinsic Value_3Y_min---15.121--------
Intrinsic Value_5Y_max--35.054--------
Intrinsic Value_5Y_min--29.175--------
Market Cap4367845.980+57%1896614.9061571260.703+21%768625.818+147%4922580.892-61%2869617.752-34%
Net Profit Margin----1.6360%-2.4370%-2.5800%-2.1500%
Operating Margin----1.7690%0.617-100%-1.8370%-1.6910%
Operating Ratio---1.769-100%-0.6300%3.367-100%3.209-100%
Pb Ratio20.834+98%0.4290.301+42%0.041+943%0.589-27%0.302+42%
Pe Ratio-4.513-4755%-0.093-0.065-30%-0.031-67%-0.124+33%-0.064-31%
Price Per Share8.730+98%0.1801.339-87%1.536-88%7.860-98%4.746-96%
Price To Free Cash Flow Ratio-4.409-4755%-0.091-0.065-28%-0.009-90%-0.236+160%-0.220+142%
Price To Total Gains Ratio-10.284-4755%-0.212-0.148-30%0.126-268%0.053-497%0.003-7647%
Quick Ratio--1.3181.694-22%3.273-60%2.329-43%2.917-55%
Return On Assets---0.337-0.339+1%0.176-291%-0.077-77%-0.117-65%
Return On Equity---1.154-1.019-12%0.315-466%-0.713-38%-0.488-58%
Total Gains Per Share---0.849-7.245+753%-0.518-39%-0.962+13%0.506-268%
Usd Book Value--4420000.0006801750.000-35%18050250.000-76%10983300.000-60%39655000.000-89%
Usd Book Value Change Per Share---0.849-7.249+754%-0.522-39%-1.952+130%0.010-8204%
Usd Book Value Per Share--0.4198.750-95%36.077-99%18.910-98%77.737-99%
Usd Dividend Per Share---0.004-100%0.004-100%0.991-100%0.495-100%
Usd Enterprise Value---1076385.094981760.703-210%9532375.818-111%4282280.892-125%8128960.912-113%
Usd Eps---0.484-5.976+1136%-13.427+2677%-10.570+2086%-22.982+4652%
Usd Free Cash Flow---5222000.000-5819750.000+11%-3110250.000-40%-5386500.000+3%-9454900.000+81%
Usd Free Cash Flow Per Share---0.495-5.607+1033%-6.216+1156%-9.282+1775%-18.156+3567%
Usd Free Cash Flow To Equity Per Share---0.030-3.688+12328%-1.744+5779%-1.121+3678%-0.631+2026%
Usd Market Cap4367845.980+57%1896614.9061571260.703+21%768625.818+147%4922580.892-61%2869617.752-34%
Usd Price Per Share8.730+98%0.1801.339-87%1.536-88%7.860-98%4.746-96%
Usd Profit---5101000.000-5930250.000+16%6870000.000-174%-2012100.000-61%-8525400.000+67%
Usd Revenue---225500.000-100%-778500.0000%1778250.000-100%5621350.000-100%
Usd Total Gains Per Share---0.849-7.245+753%-0.518-39%-0.962+13%0.506-268%
 EOD+5 -3MRQTTM+20 -16YOY+12 -235Y+16 -2110Y+13 -24

3.3 Fundamental Score

Let's check the fundamental score of Aptevo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.513
Price to Book Ratio (EOD)Between0-120.834
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.318
Current Ratio (MRQ)Greater than11.702
Debt to Asset Ratio (MRQ)Less than10.708
Debt to Equity Ratio (MRQ)Less than12.427
Return on Equity (MRQ)Greater than0.15-1.154
Return on Assets (MRQ)Greater than0.05-0.337
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Aptevo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.310
Ma 20Greater thanMa 509.930
Ma 50Greater thanMa 1008.785
Ma 100Greater thanMa 20010.853
OpenGreater thanClose9.640
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Fundamental data was last updated by Penke on 2024-12-05 12:40:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aptevo Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-163.6%+163.6%
TTM-163.6%YOY-243.7%+80.1%
TTM-163.6%5Y-258.0%+94.3%
5Y-258.0%10Y-215.0%-42.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--109.4%+109.4%
TTM-163.6%-221.4%+57.8%
YOY-243.7%-208.7%-35.0%
5Y-258.0%-346.2%+88.2%
10Y-215.0%-470.4%+255.4%
4.3.1.2. Return on Assets

Shows how efficient Aptevo Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • -33.7% Return on Assets means that Aptevo Therapeutics Inc generated $-0.34 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aptevo Therapeutics Inc:

  • The MRQ is -33.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -33.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-33.7%TTM-33.9%+0.2%
TTM-33.9%YOY17.6%-51.5%
TTM-33.9%5Y-7.7%-26.2%
5Y-7.7%10Y-11.7%+4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.7%-11.6%-22.1%
TTM-33.9%-12.0%-21.9%
YOY17.6%-11.2%+28.8%
5Y-7.7%-12.6%+4.9%
10Y-11.7%-14.2%+2.5%
4.3.1.3. Return on Equity

Shows how efficient Aptevo Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • -115.4% Return on Equity means Aptevo Therapeutics Inc generated $-1.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aptevo Therapeutics Inc:

  • The MRQ is -115.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -101.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-115.4%TTM-101.9%-13.5%
TTM-101.9%YOY31.5%-133.4%
TTM-101.9%5Y-71.3%-30.6%
5Y-71.3%10Y-48.8%-22.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-115.4%-14.5%-100.9%
TTM-101.9%-16.0%-85.9%
YOY31.5%-14.6%+46.1%
5Y-71.3%-18.6%-52.7%
10Y-48.8%-19.3%-29.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aptevo Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aptevo Therapeutics Inc is operating .

  • Measures how much profit Aptevo Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-176.9%+176.9%
TTM-176.9%YOY61.7%-238.6%
TTM-176.9%5Y-183.7%+6.7%
5Y-183.7%10Y-169.1%-14.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--203.3%+203.3%
TTM-176.9%-316.3%+139.4%
YOY61.7%-216.5%+278.2%
5Y-183.7%-378.6%+194.9%
10Y-169.1%-480.3%+311.2%
4.3.2.2. Operating Ratio

Measures how efficient Aptevo Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.769-1.769
TTM1.769YOY-0.630+2.399
TTM1.7695Y3.367-1.598
5Y3.36710Y3.209+0.159
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.284-2.284
TTM1.7693.198-1.429
YOY-0.6303.263-3.893
5Y3.3674.651-1.284
10Y3.2096.419-3.210
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aptevo Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aptevo Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.70 means the company has $1.70 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 1.702. The company is able to pay all its short-term debts. +1
  • The TTM is 2.007. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.702TTM2.007-0.304
TTM2.007YOY3.610-1.603
TTM2.0075Y2.562-0.556
5Y2.56210Y2.881-0.318
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7023.601-1.899
TTM2.0073.872-1.865
YOY3.6104.655-1.045
5Y2.5625.973-3.411
10Y2.8816.258-3.377
4.4.3.2. Quick Ratio

Measures if Aptevo Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.32 means the company can pay off $1.32 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 1.318. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.694. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.318TTM1.694-0.375
TTM1.694YOY3.273-1.579
TTM1.6945Y2.329-0.636
5Y2.32910Y2.917-0.588
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3183.093-1.775
TTM1.6943.416-1.722
YOY3.2734.393-1.120
5Y2.3295.954-3.625
10Y2.9176.436-3.519
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aptevo Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aptevo Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aptevo Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.71 means that Aptevo Therapeutics Inc assets are financed with 70.8% credit (debt) and the remaining percentage (100% - 70.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.708. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.643. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.708TTM0.643+0.065
TTM0.643YOY0.426+0.216
TTM0.6435Y0.659-0.016
5Y0.65910Y0.506+0.152
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7080.345+0.363
TTM0.6430.346+0.297
YOY0.4260.311+0.115
5Y0.6590.365+0.294
10Y0.5060.382+0.124
4.5.4.2. Debt to Equity Ratio

Measures if Aptevo Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 242.7% means that company has $2.43 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 2.427. The company is just not able to pay all its debts with equity.
  • The TTM is 1.923. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.427TTM1.923+0.504
TTM1.923YOY0.757+1.165
TTM1.9235Y4.949-3.026
5Y4.94910Y2.800+2.148
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4270.393+2.034
TTM1.9230.431+1.492
YOY0.7570.384+0.373
5Y4.9490.452+4.497
10Y2.8000.497+2.303
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aptevo Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.09 means the investor is paying $-0.09 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aptevo Therapeutics Inc:

  • The EOD is -4.513. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.093. Based on the earnings, the company is expensive. -2
  • The TTM is -0.065. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.513MRQ-0.093-4.420
MRQ-0.093TTM-0.065-0.028
TTM-0.065YOY-0.031-0.034
TTM-0.0655Y-0.124+0.059
5Y-0.12410Y-0.064-0.060
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.513-2.259-2.254
MRQ-0.093-2.480+2.387
TTM-0.065-3.148+3.083
YOY-0.031-3.244+3.213
5Y-0.124-5.991+5.867
10Y-0.064-6.692+6.628
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aptevo Therapeutics Inc:

  • The EOD is -4.409. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.091. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.065. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.409MRQ-0.091-4.318
MRQ-0.091TTM-0.065-0.026
TTM-0.065YOY-0.009-0.056
TTM-0.0655Y-0.236+0.171
5Y-0.23610Y-0.220-0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.409-2.995-1.414
MRQ-0.091-3.289+3.198
TTM-0.065-3.668+3.603
YOY-0.009-4.472+4.463
5Y-0.236-8.001+7.765
10Y-0.220-9.190+8.970
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aptevo Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.43 means the investor is paying $0.43 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aptevo Therapeutics Inc:

  • The EOD is 20.834. Based on the equity, the company is expensive. -2
  • The MRQ is 0.429. Based on the equity, the company is cheap. +2
  • The TTM is 0.301. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD20.834MRQ0.429+20.405
MRQ0.429TTM0.301+0.128
TTM0.301YOY0.041+0.260
TTM0.3015Y0.589-0.287
5Y0.58910Y0.302+0.287
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.8342.001+18.833
MRQ0.4292.054-1.625
TTM0.3012.385-2.084
YOY0.0412.431-2.390
5Y0.5893.690-3.101
10Y0.3024.307-4.005
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aptevo Therapeutics Inc.

4.8.1. Institutions holding Aptevo Therapeutics Inc

Institutions are holding 11.357% of the shares of Aptevo Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Hudson Bay Capital Management LP5.05370.000793555243555287.1104
2024-06-30Sabby Management LLC2.7090.10325014995014990
2024-09-30Citadel Advisors Llc0.60301116321116320
2024-09-30Geode Capital Management, LLC0.23604368424299125.3495
2024-09-30Renaissance Technologies Corp0.1976036575365750
2024-09-30HRT FINANCIAL LLC0.1519028116-2444-7.9974
2024-09-30TWO SIGMA SECURITIES, LLC0.15140.000128020280200
2024-09-30Tower Research Capital LLC0.13540.00012506917331223.9726
2024-06-30Virtu Financial LLC0.0940.000417395173950
2024-09-30Two Sigma Investments LLC0.0767014195141950
2024-06-30BlackRock Inc0.00480888-2-0.2247
2024-09-30Morgan Stanley - Brokerage Accounts0.0010194-194-50
2024-06-30Bank of America Corp0.000901601600
2024-06-30Advisor Group Holdings, Inc.0.000204500
2024-09-30JPMorgan Chase & Co0.000204300
2024-09-30Wells Fargo & Co0.000203300
2024-09-30PNC Financial Services Group Inc00300
2024-09-30Truvestments Capital LLC00220
2024-09-30Baader Bank INC000-20152-100
2024-09-30UBS Group AG000-115910-100
Total 9.4160.10451743105+1047958+60.1%

4.9.2. Funds holding Aptevo Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Fidelity Extended Market Index0.23604368424638129.3605
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr0.01130208400
2024-06-30CIMA Global Value SICAV0.00170.000431900
2024-09-30Franklin U.S. Small Cap Equity I0.0013023300
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.000407900
2024-09-30NT Quality Small Cap Core0.000407800
2024-06-30NT Quality SCC US Fund - L0.0004078-1-1.2658
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.000306400
2024-09-30BNYM Mellon SL Market Completion UC10.000203700
2024-10-31State St US Extended Mkt Indx NL Cl C0.000101600
2024-09-30SAST SA Franklin Tactical Oppos Port 10.000101600
2024-06-30SSgA U.S. Total Market Index Strategy007240
2024-09-30NT Ext Equity Mkt Idx Fd - L00400
2024-09-30BNYM Mellon NSL Mkt Completion Fund Inst00220
Total 0.25220.000446701+24641+52.8%

5.3. Insider Transactions

Insiders are holding 0.028% of the shares of Aptevo Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-11-22Kevin C TangSELL5802309.32
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets15,146
Total Liabilities10,726
Total Stockholder Equity4,420
 As reported
Total Liabilities 10,726
Total Stockholder Equity+ 4,420
Total Assets = 15,146

Assets

Total Assets15,146
Total Current Assets10,012
Long-term Assets5,134
Total Current Assets
Cash And Cash Equivalents 7,753
Other Current Assets 2,259
Total Current Assets  (as reported)10,012
Total Current Assets  (calculated)10,012
+/-0
Long-term Assets
Property Plant Equipment 5,134
Long-term Assets  (as reported)5,134
Long-term Assets  (calculated)5,134
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,882
Long-term Liabilities4,844
Total Stockholder Equity4,420
Total Current Liabilities
Accounts payable 3,532
Other Current Liabilities 2,350
Total Current Liabilities  (as reported)5,882
Total Current Liabilities  (calculated)5,882
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt4,830
Long-term Liabilities Other 14
Long-term Liabilities  (as reported)4,844
Long-term Liabilities  (calculated)4,844
+/-0
Total Stockholder Equity
Common Stock82
Retained Earnings -241,265
Other Stockholders Equity 245,603
Total Stockholder Equity (as reported)4,420
Total Stockholder Equity (calculated)4,420
+/-0
Other
Capital Stock82
Cash and Short Term Investments 7,753
Common Stock Shares Outstanding 10,548
Liabilities and Stockholders Equity 15,146
Net Debt -2,923
Net Invested Capital 4,420
Net Working Capital 4,130
Property Plant and Equipment Gross 5,134
Short Long Term Debt Total 4,830



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
119,971
0
0
0
112,456
141,589
118,159
100,623
91,858
97,793
86,891
131,022
117,007
100,212
89,997
78,934
67,494
80,841
66,127
60,556
53,408
25,244
18,509
37,420
53,547
68,753
71,474
64,005
56,601
45,184
38,799
31,695
34,215
34,969
28,912
27,129
24,842
17,629
14,921
15,146
15,14614,92117,62924,84227,12928,91234,96934,21531,69538,79945,18456,60164,00571,47468,75353,54737,42018,50925,24453,40860,55666,12780,84167,49478,93489,997100,212117,007131,02286,89197,79391,858100,623118,159141,589112,456000119,971
   > Total Current Assets 
41,551
3,593
0
0
35,134
64,407
39,847
79,429
71,414
77,396
67,193
115,322
95,084
77,160
66,247
60,395
48,689
57,642
43,672
36,789
29,995
14,825
10,488
30,653
47,264
62,850
65,765
58,873
52,570
41,672
31,400
24,618
27,450
28,485
22,680
21,126
19,066
12,074
9,579
10,012
10,0129,57912,07419,06621,12622,68028,48527,45024,61831,40041,67252,57058,87365,76562,85047,26430,65310,48814,82529,99536,78943,67257,64248,68960,39566,24777,16095,084115,32267,19377,39671,41479,42939,84764,40735,134003,59341,551
       Cash And Cash Equivalents 
3,593
-3,593
0
0
4,637
45,000
5,496
10,894
9,676
14,014
22,269
75,830
7,095
11,830
7,228
28,447
30,635
37,011
20,957
17,683
12,448
12,258
7,599
24,942
39,979
57,524
60,394
52,118
45,044
34,991
29,431
22,150
22,635
25,328
21,006
19,110
16,904
10,250
8,066
7,753
7,7538,06610,25016,90419,11021,00625,32822,63522,15029,43134,99145,04452,11860,39457,52439,97924,9427,59912,25812,44817,68320,95737,01130,63528,4477,22811,8307,09575,83022,26914,0149,67610,8945,49645,0004,63700-3,5933,593
       Short-term Investments 
0
7,186
0
0
0
0
400
49,785
44,849
46,877
25,958
20,946
73,688
49,824
37,503
9,192
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000009,19237,50349,82473,68820,94625,95846,87744,84949,78540000007,1860
       Net Receivables 
15,130
0
0
0
7,832
4,845
9,913
2,958
4,284
1,926
4,715
528
2,141
3,098
6,145
6,202
5,220
5,801
7,378
7,918
7,022
7,022
288
1,463
2,369
2,421
3,110
3,096
3,664
3,114
0
0
2,500
0
0
0
0
0
0
0
00000002,500003,1143,6643,0963,1102,4212,3691,4632887,0227,0227,9187,3785,8015,2206,2026,1453,0982,1415284,7151,9264,2842,9589,9134,8457,83200015,130
       Inventory 
17,625
0
0
0
20,322
9,127
20,130
11,574
6,639
8,063
7,984
1,237
1,028
1,285
2,970
3,969
1,785
4,346
6,967
7,482
6,139
6,139
2,503
4,042
4,783
2,822
2,195
3,650
3,082
2,690
0
0
1,571
0
0
0
0
0
0
0
00000001,571002,6903,0823,6502,1952,8224,7834,0422,5036,1396,1397,4826,9674,3461,7853,9692,9701,2851,0281,2377,9848,0636,63911,57420,1309,12720,32200017,625
       Other Current Assets 
5,203
0
0
0
2,343
5,435
4,308
4,218
5,966
6,516
6,267
16,781
6,710
6,630
7,138
6,990
4,142
3,561
3,170
1,491
160
1,224
98
206
133
83
66
9
780
877
768
658
744
1,582
764
649
2,162
1,824
1,513
2,259
2,2591,5131,8242,1626497641,58274465876887778096683133206981,2241601,4913,1703,5614,1426,9907,1386,6306,71016,7816,2676,5165,9664,2184,3085,4352,3430005,203
   > Long-term Assets 
0
-3,593
0
0
77,322
77,182
78,312
21,194
20,444
20,397
19,698
15,700
21,923
23,052
23,750
18,539
18,805
23,199
22,455
23,767
23,413
10,419
8,021
6,767
6,283
5,903
5,709
5,132
4,031
3,512
7,399
7,077
6,765
6,484
6,232
6,003
5,776
5,555
5,342
5,134
5,1345,3425,5555,7766,0036,2326,4846,7657,0777,3993,5124,0315,1325,7095,9036,2836,7678,02110,41923,41323,76722,45523,19918,80518,53923,75023,05221,92315,70019,69820,39720,44421,19478,31277,18277,32200-3,5930
       Property Plant Equipment 
3,202
0
0
0
4,179
4,624
6,342
6,139
5,910
6,384
6,205
6,163
5,843
5,936
5,638
5,608
5,202
9,459
8,874
8,252
7,693
7,133
6,571
6,010
5,537
5,157
4,963
4,386
3,963
3,444
7,399
7,077
6,765
6,484
6,232
6,003
5,776
5,555
5,342
5,134
5,1345,3425,5555,7766,0036,2326,4846,7657,0777,3993,4443,9634,3864,9635,1575,5376,0106,5717,1337,6938,2528,8749,4595,2025,6085,6385,9365,8436,1636,2056,3845,9106,1396,3424,6244,1790003,202
       Goodwill 
13,902
0
0
0
13,902
13,902
13,902
0
0
0
0
0
0
0
0
0
0
0
0
0
-830
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000-830000000000000013,90213,90213,90200013,902
       Intangible Assets 
75,218
0
0
0
59,241
58,656
58,068
15,055
14,534
14,013
13,493
6,287
6,080
5,873
5,665
5,458
5,250
5,043
4,835
4,628
5,250
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000005,2504,6284,8355,0435,2505,4585,6655,8736,0806,28713,49314,01314,53415,05558,06858,65659,24100075,218
       Long-term Assets Other 
0
-3,593
0
0
0
0
-506
15,055
14,534
0
0
3,250
10,000
11,243
12,447
7,473
8,353
8,697
8,746
10,887
11,300
3,286
1,450
757
746
746
746
746
68
68
-7,399
-7,077
-6,765
-6,484
-6,232
0
0
0
0
0
00000-6,232-6,484-6,765-7,077-7,39968687467467467467571,4503,28611,30010,8878,7468,6978,3537,47312,44711,24310,0003,2500014,53415,055-5060000-3,5930
> Total Liabilities 
25,363
0
0
0
23,838
22,743
20,962
36,873
41,292
36,307
35,471
40,712
34,972
31,848
33,967
34,934
37,088
41,711
39,928
40,811
41,566
10,092
9,859
35,218
36,953
58,249
57,593
56,713
55,385
51,068
15,752
15,933
16,241
11,713
12,659
12,411
12,621
11,526
10,458
10,726
10,72610,45811,52612,62112,41112,65911,71316,24115,93315,75251,06855,38556,71357,59358,24936,95335,2189,85910,09241,56640,81139,92841,71137,08834,93433,96731,84834,97240,71235,47136,30741,29236,87320,96222,74323,83800025,363
   > Total Current Liabilities 
19,835
0
0
0
19,943
18,690
17,028
15,233
19,544
14,459
11,883
14,870
18,510
17,273
18,102
15,442
17,610
18,290
16,598
37,252
38,239
6,993
7,002
7,417
14,539
29,344
30,864
32,380
34,757
23,857
7,003
7,786
8,706
5,797
6,911
6,836
7,224
6,298
5,419
5,882
5,8825,4196,2987,2246,8366,9115,7978,7067,7867,00323,85734,75732,38030,86429,34414,5397,4177,0026,99338,23937,25216,59818,29017,61015,44218,10217,27318,51014,87011,88314,45919,54415,23317,02818,69019,94300019,835
       Short-term Debt 
0
0
0
0
5,572
4,142
5,251
-8,951
18,383
18,435
18,745
17,484
3,333
5,333
4,167
0
0
1,081
0
19,707
19,863
19,863
0
0
5,000
10,167
10,667
11,167
11,667
2,000
2,000
2,000
2,000
0
0
0
0
0
0
0
00000002,0002,0002,0002,00011,66711,16710,66710,1675,0000019,86319,86319,70701,081004,1675,3333,33317,48418,74518,43518,383-8,9515,2514,1425,5720000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
18,383
18,435
18,745
17,484
3,333
5,333
4,167
0
0
1,081
0
19,707
19,863
0
0
0
5,000
10,167
10,667
11,167
11,667
2,000
2,000
2,000
2,000
0
0
0
0
0
0
0
00000002,0002,0002,0002,00011,66711,16710,66710,1675,00000019,86319,70701,081004,1675,3333,33317,48418,74518,43518,38300000000
       Accounts payable 
11,472
0
0
0
10,084
12,197
11,192
8,951
15,498
11,271
8,293
11,327
7,350
7,263
9,535
9,808
11,671
11,043
11,904
12,073
13,043
5,001
4,662
3,911
5,583
5,352
5,196
3,687
3,462
3,910
3,269
3,243
3,499
4,134
4,873
4,000
3,984
3,720
3,736
3,532
3,5323,7363,7203,9844,0004,8734,1343,4993,2433,2693,9103,4623,6875,1965,3525,5833,9114,6625,00113,04312,07311,90411,04311,6719,8089,5357,2637,35011,3278,29311,27115,4988,95111,19212,19710,08400011,472
       Other Current Liabilities 
8,363
0
0
0
444
233
191
5,642
18,733
13,581
10,439
14,870
7,827
1,696
762
5,634
5,939
7,247
4,694
1,121
1,083
1,992
2,340
3,506
3,956
12,729
15,001
17,526
19,628
16,907
30
2,543
6,706
1,663
2,038
2,836
3,240
2,578
1,683
2,350
2,3501,6832,5783,2402,8362,0381,6636,7062,5433016,90719,62817,52615,00112,7293,9563,5062,3401,9921,0831,1214,6947,2475,9395,6347621,6967,82714,87010,43913,58118,7335,6421912334440008,363
   > Long-term Liabilities 
0
0
0
0
3,895
4,053
3,934
21,640
21,748
21,848
23,588
25,842
16,462
14,575
15,865
19,492
19,478
23,421
23,330
3,559
3,327
3,099
2,857
27,801
22,414
28,905
26,729
24,333
20,628
27,211
8,749
8,147
7,535
5,916
5,748
5,575
5,397
5,228
5,039
4,844
4,8445,0395,2285,3975,5755,7485,9167,5358,1478,74927,21120,62824,33326,72928,90522,41427,8012,8573,0993,3273,55923,33023,42119,47819,49215,86514,57516,46225,84223,58821,84821,74821,6403,9344,0533,8950000
       Long term Debt Total 
0
0
0
0
0
0
0
18,111
18,383
18,435
18,745
17,484
15,728
13,975
15,400
19,143
19,278
19,415
19,558
0
0
0
0
25,199
0
4,614
4,323
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000004,3234,614025,199000019,55819,41519,27819,14315,40013,97515,72817,48418,74518,43518,38318,1110000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-5,572
-4,142
-5,251
8,951
-18,383
-18,435
-18,745
-17,484
-3,333
-5,333
-4,167
0
0
2,914
3,759
-16,160
-16,536
-16,764
2,857
2,602
-2,640
-8,048
-8,798
-9,557
-10,326
-935
4,390
4,237
4,079
5,916
5,748
5,575
5,397
5,214
5,025
4,830
4,8305,0255,2145,3975,5755,7485,9164,0794,2374,390-935-10,326-9,557-8,798-8,048-2,6402,6022,857-16,764-16,536-16,1603,7592,91400-4,167-5,333-3,333-17,484-18,745-18,435-18,3838,951-5,251-4,142-5,5720000
       Long-term Liabilities Other 
0
0
0
0
0
0
88
433
469
611
2,047
8,358
734
600
465
349
200
4,006
13
12
3,327
3,099
2,857
2,602
0
24,291
20,537
18,711
15,580
23,342
0
0
0
0
0
0
0
14
14
14
141414000000023,34215,58018,71120,53724,29102,6022,8573,0993,32712134,0062003494656007348,3582,04761146943388000000
       Deferred Long Term Liability 
0
0
0
0
19,135
0
3,846
3,096
2,896
2,802
2,796
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000002,7962,8022,8963,0963,846019,1350000
> Total Stockholder Equity
94,608
94,608
0
0
88,618
118,846
97,197
63,750
50,566
61,486
51,420
90,310
82,035
68,364
56,030
44,000
30,406
39,130
26,199
19,745
11,842
15,152
8,650
2,202
16,594
10,504
13,881
7,292
1,216
-5,884
23,047
15,762
17,974
23,256
16,253
14,718
12,221
6,103
4,463
4,420
4,4204,4636,10312,22114,71816,25323,25617,97415,76223,047-5,8841,2167,29213,88110,50416,5942,2028,65015,15211,84219,74526,19939,13030,40644,00056,03068,36482,03590,31051,42061,48650,56663,75097,197118,84688,6180094,60894,608
   Common Stock
267,279
0
0
0
320,606
20
354,913
20
20
21
21
21
22
22
23
23
23
45
45
45
45
45
45
45
46
46
47
47
47
47
47
47
48
49
49
56
61
66
69
82
826966615649494847474747474746464545454545454523232322222121212020354,91320320,606000267,279
   Retained Earnings -241,265-236,164-230,281-223,447-217,545-211,211-203,263-206,036-201,394-193,750-221,760-214,063-207,791-200,794-192,862-185,606-178,553-171,762-164,959-167,856-159,682-152,758-139,426-127,408-113,279-100,717-87,573-73,719-63,958-101,826-90,637-80,692-65,746-257,716-244,878-231,988000-172,671
   Capital Surplus 
0
0
0
0
0
0
0
149,493
151,271
152,143
153,239
154,257
155,837
155,998
156,760
157,258
157,791
178,511
178,912
179,382
179,653
180,066
180,367
180,710
0
203,320
214,628
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000214,628203,3200180,710180,367180,066179,653179,382178,912178,511157,791157,258156,760155,998155,837154,257153,239152,143151,271149,4930000000
   Treasury Stock0000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
320,606
363,704
354,913
129,493
131,271
152,143
153,239
154,257
155,837
155,998
156,760
157,258
157,791
178,511
178,912
179,382
179,653
180,066
180,367
180,710
202,154
203,320
214,628
215,036
215,232
215,829
216,750
217,109
223,962
226,470
227,415
232,207
235,607
236,318
240,558
245,603
245,603240,558236,318235,607232,207227,415226,470223,962217,109216,750215,829215,232215,036214,628203,320202,154180,710180,367180,066179,653179,382178,912178,511157,791157,258156,760155,998155,837154,257153,239152,143131,271129,493354,913363,704320,6060000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.